Terumo Medical Corporation Obtains Withdrawal By Vascular Solutions Of The R-Band™ Radial Hemostasis Device

  Terumo Medical Corporation Obtains Withdrawal By Vascular Solutions Of The
                       R-Band™ Radial Hemostasis Device

Court Enters Order Under Which Vascular Solutions Will Cease Manufacture,
Sales and Distribution of R-Band

PR Newswire

SOMERSET, N.J., May 21, 2013

SOMERSET, N.J., May 21, 2013 /PRNewswire/ --Terumo Medical Corporation
(Terumo), today announced that it was pleased with the U.S. District Court for
the District of New Jersey's Order approving an agreement of the parties under
which Vascular Solutions Inc. will cease further manufacture, sales, and
distribution of its R-Band™ Radial Hemostasis Device, pending litigation of
Terumo's claims.

In February, Terumo filed a patent infringement lawsuit alleging that the R
Band™ Radial Hemostasis Device infringes on U.S. patent and trademark rights
held by Terumo Medical Corporation for its proprietary TR Band™ Radial
Compression Device. The R-Band is distributed in the U.S. by Vascular
Solutions and manufactured by Lepu Medical Technology. Terumo sought an
injunction against further sales of the infringing product.

"Terumo is extremely gratified with the Court's Order. We are thankful for the
opportunity to successfully defend our TR Band™ device, which is a critical
part of our transradial solutions portfolio," said James Rushworth, President,
Terumo Interventional Systems and Onset Medical Corporation. "As a market
leader, Terumo is committed to doing what is right for our business and, when
appropriate, we will vigorously protect our investments, assets and
intellectual property."

Terumo's market-leading TR Band™ Radial Compression Device is used to achieve
patent hemostasis immediately following a transradial access diagnostic and
intervention in the treatment of cardiac and vascular disease. The clear band
is placed around the patient's wrist to effectively stop access-point
bleeding. The TR Band™ features dual compression balloons that maintain
precise pressure on the radial artery to ensure blood return without
compromising local nerve structure. Transradial access interventions have been
shown to significantly reduce bleeding complications by up to 75 percent when
compared to femoral (through the groin) interventions.

Terumo Interventional Systems
Terumo Interventional Systems (TIS) is a strategic business unit of Terumo
Medical Corporation. As a market leader in entry site management and lesion
access, TIS is committed to pursuing unique technologies designed to enhance
treatment of coronary and peripheral endovascular diseases as well as driving
strategic initiatives focused on Critical Limb Ischemia, Complex Coronary
Intervention and Transradial Access. Terumo® Urology, a dedicated group within
TIS, focuses on direct sales, marketing, support and distribution of key
products to the urological specialty.

TIS directly markets a full line of guidewires, catheters, introducer sheaths,
guiding sheaths and embolization products for use in a multitude of different
interventional procedures.

Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation
(TMC) develops, manufactures, and markets a complete, solutions-based
portfolio of high-quality medical devices used in a broad range of
applications for numerous areas of the healthcare industry. TMC is comprised
of two business divisions: Terumo Interventional Systems and Terumo Medical
Products. The company places a premium on providing customers with world-class
products, training and education programs that drive clear economic value,
better clinical outcomes and improved Quality of Life for patients.

Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device
manufacturers with $5 billion in sales and operations in more than 160
nations. Founded in 1921, the company develops, manufactures, and distributes
world-class medical devices including products for use in cardiothoracic
surgery, interventional procedures, and transfusion medicine; the company also
manufactures a broad array of syringe and hypodermic needle products for
hospital and physician office use. Terumo contributes to society by providing
valued products and services to the healthcare market and by responding to the
needs of healthcare providers and the people they serve.

Terumo Corporation's shares are listed on the first section of the Tokyo Stock
Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a
component of the Nikkei 225, Japan's leading stock index.

SOURCE Terumo Medical Corporation

Contact: Robert Murphy, Jitsu Public Relations, Inc., (908) 276-0777,
rmurphy@jitsuPR.com
 
Press spacebar to pause and continue. Press esc to stop.